USANA Health Sciences (NYSE:USNA – Get Free Report) released its earnings results on Tuesday. The company reported $0.54 EPS for the quarter, missing the consensus estimate of $0.65 by ($0.11), RTT News reports. USANA Health Sciences had a return on equity of 11.26% and a net margin of 6.29%. The firm had revenue of $212.87 million during the quarter, compared to analyst estimates of $218.64 million. During the same quarter last year, the business posted $0.89 EPS. USANA Health Sciences updated its FY 2024 guidance to 2.400-2.550 EPS.
USANA Health Sciences Trading Down 3.2 %
Shares of NYSE USNA traded down $1.43 during midday trading on Thursday, reaching $43.06. 25,658 shares of the stock were exchanged, compared to its average volume of 79,679. The company has a market capitalization of $820.29 million, a P/E ratio of 13.86, a P/E/G ratio of 1.38 and a beta of 0.90. USANA Health Sciences has a 52-week low of $40.51 and a 52-week high of $69.60. The stock has a 50 day moving average price of $46.34 and a 200-day moving average price of $47.09.
Insider Transactions at USANA Health Sciences
In related news, insider Daniel A. Macuga sold 3,791 shares of the firm’s stock in a transaction that occurred on Thursday, May 2nd. The shares were sold at an average price of $47.14, for a total value of $178,707.74. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In other USANA Health Sciences news, insider Daniel A. Macuga sold 3,791 shares of USANA Health Sciences stock in a transaction that occurred on Thursday, May 2nd. The shares were sold at an average price of $47.14, for a total transaction of $178,707.74. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, major shareholder Myron W. Wentz sold 13,496 shares of the company’s stock in a transaction on Friday, June 14th. The shares were sold at an average price of $45.03, for a total transaction of $607,724.88. Following the completion of the transaction, the insider now owns 7,864,345 shares of the company’s stock, valued at $354,131,455.35. The disclosure for this sale can be found here. Insiders sold a total of 31,591 shares of company stock worth $1,458,098 over the last ninety days. 0.33% of the stock is currently owned by corporate insiders.
Analyst Ratings Changes
View Our Latest Research Report on USNA
About USANA Health Sciences
USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.
See Also
- Five stocks we like better than USANA Health Sciences
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Top 3 Small Cap Stocks Emerging as Rotation Winners
- What Are Dividends? Buy the Best Dividend Stocks
- Bargain Alert: 3 Stocks Worth Watching While The Market Cools
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Qualcomm Stock Could Be On The Verge of an Impressive Rally
Receive News & Ratings for USANA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.